Eisai Co Ltd

Newron Pharmaceuticals reveals Evenamide’s breakthrough glutamate‑modulating data ahead of SIRS 2026, positioning a first‑in‑class therapy for treatment‑resistant schizophrenia, with strategic pricing, patent, and partnership plans that could drive …

Discover how Eisai’s lecanemab presentation at AD/PD 2026 will shape Alzheimer’s treatment—clinical breakthroughs, reimbursement insights, and market strategy revealed.

WELIREG + Lenvima’s 30% PFS boost in RCC promises higher U.S. reimbursement, first‑mover advantage and $600 M annual sales – learn how Eisai will capture this growing market.

Discover how Eisai’s Kompass platform and Leqembi therapy blend digital health, patient care, and oncology‑neuro synergy to reshape pharma.

How Eisai’s Lecanemab review shows the cost‑benefit gap in Alzheimer’s drugs—and why Germany’s value‑based reimbursement forces pharma to prove real clinical value.

Read how Eisai’s orphan‑drug designation for E2086 could unlock Japan’s growing narcolepsy market and the cost‑benefit challenges ahead.

Explore how Eisai’s new co‑exclusive deals with Henlius and Fosun bolster its anti‑PD‑1 pipeline, mitigate patent cliffs, and aim for a 10‑15 % sales lift by 2029.

Discover how Eisai’s EMA IV‑maintenance and FDA SC‑autoinjector approvals could improve Alzheimer’s therapy access, boost patient adherence, and expand market reach.

Priority review for Eisai’s Leqembi autoinjector accelerates at‑home Alzheimer’s treatment, boosting patient convenience, potential market share, and strategic momentum.

Explore how Eisai’s diversified portfolio and breakthrough trials are boosting investor confidence, with highlights on Alzheimer’s, oncology and neuroinflammation research.